img

Global Peptides Biosimilars Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Peptides Biosimilars Market Insights, Forecast to 2034

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The statistic scope in this report is peptides biosimilars.
Market Analysis and InsightsGlobal Peptides Biosimilars Market
Global Peptides Biosimilars market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Peptides Biosimilars industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Peptides Biosimilars market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Peptides Biosimilars market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
Segment by Type
Glucagon
Calcitonin

Segment by Application


Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Peptides Biosimilars introduction, etc. Peptides Biosimilars Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Peptides Biosimilars
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptides Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Glucagon
1.2.3 Calcitonin
1.3 Market by Application
1.3.1 Global Peptides Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptides Biosimilars Market Perspective (2018-2033)
2.2 Global Peptides Biosimilars Growth Trends by Region
2.2.1 Peptides Biosimilars Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Peptides Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Peptides Biosimilars Forecasted Market Size by Region (2024-2033)
2.3 Peptides Biosimilars Market Dynamics
2.3.1 Peptides Biosimilars Industry Trends
2.3.2 Peptides Biosimilars Market Drivers
2.3.3 Peptides Biosimilars Market Challenges
2.3.4 Peptides Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Peptides Biosimilars by Players
3.1.1 Global Peptides Biosimilars Revenue by Players (2018-2023)
3.1.2 Global Peptides Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Peptides Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Peptides Biosimilars, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Peptides Biosimilars Market Concentration Ratio
3.4.1 Global Peptides Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptides Biosimilars Revenue in 2022
3.5 Global Key Players of Peptides Biosimilars Head office and Area Served
3.6 Global Key Players of Peptides Biosimilars, Product and Application
3.7 Global Key Players of Peptides Biosimilars, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptides Biosimilars Breakdown Data by Type
4.1 Global Peptides Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Peptides Biosimilars Forecasted Market Size by Type (2024-2033)
5 Peptides Biosimilars Breakdown Data by Application
5.1 Global Peptides Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Peptides Biosimilars Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Peptides Biosimilars Market Size (2018-2033)
6.2 North America Peptides Biosimilars Market Size by Type
6.2.1 North America Peptides Biosimilars Market Size by Type (2018-2023)
6.2.2 North America Peptides Biosimilars Market Size by Type (2024-2033)
6.2.3 North America Peptides Biosimilars Market Share by Type (2018-2033)
6.3 North America Peptides Biosimilars Market Size by Application
6.3.1 North America Peptides Biosimilars Market Size by Application (2018-2023)
6.3.2 North America Peptides Biosimilars Market Size by Application (2024-2033)
6.3.3 North America Peptides Biosimilars Market Share by Application (2018-2033)
6.4 North America Peptides Biosimilars Market Size by Country
6.4.1 North America Peptides Biosimilars Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Peptides Biosimilars Market Size by Country (2018-2023)
6.4.3 North America Peptides Biosimilars Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Peptides Biosimilars Market Size (2018-2033)
7.2 Europe Peptides Biosimilars Market Size by Type
7.2.1 Europe Peptides Biosimilars Market Size by Type (2018-2023)
7.2.2 Europe Peptides Biosimilars Market Size by Type (2024-2033)
7.2.3 Europe Peptides Biosimilars Market Share by Type (2018-2033)
7.3 Europe Peptides Biosimilars Market Size by Application
7.3.1 Europe Peptides Biosimilars Market Size by Application (2018-2023)
7.3.2 Europe Peptides Biosimilars Market Size by Application (2024-2033)
7.3.3 Europe Peptides Biosimilars Market Share by Application (2018-2033)
7.4 Europe Peptides Biosimilars Market Size by Country
7.4.1 Europe Peptides Biosimilars Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Peptides Biosimilars Market Size by Country (2018-2023)
7.4.3 Europe Peptides Biosimilars Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Peptides Biosimilars Market Size (2018-2033)
8.2 China Peptides Biosimilars Market Size by Type
8.2.1 China Peptides Biosimilars Market Size by Type (2018-2023)
8.2.2 China Peptides Biosimilars Market Size by Type (2024-2033)
8.2.3 China Peptides Biosimilars Market Share by Type (2018-2033)
8.3 China Peptides Biosimilars Market Size by Application
8.3.1 China Peptides Biosimilars Market Size by Application (2018-2023)
8.3.2 China Peptides Biosimilars Market Size by Application (2024-2033)
8.3.3 China Peptides Biosimilars Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Peptides Biosimilars Market Size (2018-2033)
9.2 Asia Peptides Biosimilars Market Size by Type
9.2.1 Asia Peptides Biosimilars Market Size by Type (2018-2023)
9.2.2 Asia Peptides Biosimilars Market Size by Type (2024-2033)
9.2.3 Asia Peptides Biosimilars Market Share by Type (2018-2033)
9.3 Asia Peptides Biosimilars Market Size by Application
9.3.1 Asia Peptides Biosimilars Market Size by Application (2018-2023)
9.3.2 Asia Peptides Biosimilars Market Size by Application (2024-2033)
9.3.3 Asia Peptides Biosimilars Market Share by Application (2018-2033)
9.4 Asia Peptides Biosimilars Market Size by Region
9.4.1 Asia Peptides Biosimilars Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Peptides Biosimilars Market Size by Region (2018-2023)
9.4.3 Asia Peptides Biosimilars Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Peptides Biosimilars Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Type
10.2.1 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Peptides Biosimilars Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Application
10.3.1 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Peptides Biosimilars Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country
10.4.1 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Details
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Peptides Biosimilars Introduction
11.1.4 Sandoz Revenue in Peptides Biosimilars Business (2018-2023)
11.1.5 Sandoz Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Peptides Biosimilars Introduction
11.2.4 Pfizer Revenue in Peptides Biosimilars Business (2018-2023)
11.2.5 Pfizer Recent Developments
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Details
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Peptides Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2018-2023)
11.3.5 Teva Pahrmaceutical Recent Developments
11.4 Celltrion
11.4.1 Celltrion Company Details
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Peptides Biosimilars Introduction
11.4.4 Celltrion Revenue in Peptides Biosimilars Business (2018-2023)
11.4.5 Celltrion Recent Developments
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Peptides Biosimilars Introduction
11.5.4 Biocon Revenue in Peptides Biosimilars Business (2018-2023)
11.5.5 Biocon Recent Developments
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Peptides Biosimilars Introduction
11.6.4 Amgen Revenue in Peptides Biosimilars Business (2018-2023)
11.6.5 Amgen Recent Developments
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Details
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Peptides Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Peptides Biosimilars Business (2018-2023)
11.7.5 Samsung Biologics Recent Developments
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Mylan Business Overview
11.8.3 Mylan Peptides Biosimilars Introduction
11.8.4 Mylan Revenue in Peptides Biosimilars Business (2018-2023)
11.8.5 Mylan Recent Developments
11.9 Dr. Reddy's Laboratories
11.9.1 Dr. Reddy's Laboratories Company Details
11.9.2 Dr. Reddy's Laboratories Business Overview
11.9.3 Dr. Reddy's Laboratories Peptides Biosimilars Introduction
11.9.4 Dr. Reddy's Laboratories Revenue in Peptides Biosimilars Business (2018-2023)
11.9.5 Dr. Reddy's Laboratories Recent Developments
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Details
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Peptides Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2018-2023)
11.10.5 Stada Arzneimittel AG Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Peptides Biosimilars Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Glucagon
Table 3. Key Players of Calcitonin
Table 4. Global Peptides Biosimilars Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Peptides Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Peptides Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Peptides Biosimilars Market Share by Region (2018-2023)
Table 8. Global Peptides Biosimilars Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Peptides Biosimilars Market Share by Region (2024-2033)
Table 10. Peptides Biosimilars Market Trends
Table 11. Peptides Biosimilars Market Drivers
Table 12. Peptides Biosimilars Market Challenges
Table 13. Peptides Biosimilars Market Restraints
Table 14. Global Peptides Biosimilars Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Peptides Biosimilars Revenue Share by Players (2018-2023)
Table 16. Global Top Peptides Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptides Biosimilars as of 2022)
Table 17. Global Peptides Biosimilars Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Peptides Biosimilars Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Peptides Biosimilars, Headquarters and Area Served
Table 20. Global Key Players of Peptides Biosimilars, Product and Application
Table 21. Global Key Players of Peptides Biosimilars, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Peptides Biosimilars Revenue Market Share by Type (2018-2023)
Table 25. Global Peptides Biosimilars Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Peptides Biosimilars Revenue Market Share by Type (2024-2033)
Table 27. Global Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Peptides Biosimilars Revenue Share by Application (2018-2023)
Table 29. Global Peptides Biosimilars Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Peptides Biosimilars Revenue Share by Application (2024-2033)
Table 31. North America Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Peptides Biosimilars Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Peptides Biosimilars Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Peptides Biosimilars Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Peptides Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Peptides Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Peptides Biosimilars Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Peptides Biosimilars Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Peptides Biosimilars Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Peptides Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Peptides Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Peptides Biosimilars Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Peptides Biosimilars Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Peptides Biosimilars Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Peptides Biosimilars Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Peptides Biosimilars Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Peptides Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Peptides Biosimilars Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Peptides Biosimilars Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Peptides Biosimilars Market Size by Country (2024-2033) & (US$ Million)
Table 63. Sandoz Company Details
Table 64. Sandoz Business Overview
Table 65. Sandoz Peptides Biosimilars Product
Table 66. Sandoz Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 67. Sandoz Recent Developments
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Peptides Biosimilars Product
Table 71. Pfizer Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 72. Pfizer Recent Developments
Table 73. Teva Pahrmaceutical Company Details
Table 74. Teva Pahrmaceutical Business Overview
Table 75. Teva Pahrmaceutical Peptides Biosimilars Product
Table 76. Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 77. Teva Pahrmaceutical Recent Developments
Table 78. Celltrion Company Details
Table 79. Celltrion Business Overview
Table 80. Celltrion Peptides Biosimilars Product
Table 81. Celltrion Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 82. Celltrion Recent Developments
Table 83. Biocon Company Details
Table 84. Biocon Business Overview
Table 85. Biocon Peptides Biosimilars Product
Table 86. Biocon Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 87. Biocon Recent Developments
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Peptides Biosimilars Product
Table 91. Amgen Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 92. Amgen Recent Developments
Table 93. Samsung Biologics Company Details
Table 94. Samsung Biologics Business Overview
Table 95. Samsung Biologics Peptides Biosimilars Product
Table 96. Samsung Biologics Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 97. Samsung Biologics Recent Developments
Table 98. Mylan Company Details
Table 99. Mylan Business Overview
Table 100. Mylan Peptides Biosimilars Product
Table 101. Mylan Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 102. Mylan Recent Developments
Table 103. Dr. Reddy's Laboratories Company Details
Table 104. Dr. Reddy's Laboratories Business Overview
Table 105. Dr. Reddy's Laboratories Peptides Biosimilars Product
Table 106. Dr. Reddy's Laboratories Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 107. Dr. Reddy's Laboratories Recent Developments
Table 108. Stada Arzneimittel AG Company Details
Table 109. Stada Arzneimittel AG Business Overview
Table 110. Stada Arzneimittel AG Peptides Biosimilars Product
Table 111. Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2018-2023) & (US$ Million)
Table 112. Stada Arzneimittel AG Recent Developments
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptides Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Peptides Biosimilars Market Share by Type: 2022 VS 2033
Figure 3. Glucagon Features
Figure 4. Calcitonin Features
Figure 5. Global Peptides Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Peptides Biosimilars Market Share by Application: 2022 VS 2033
Figure 7. Oncology Case Studies
Figure 8. Chronic Diseases Case Studies
Figure 9. Autoimmune Diseases Case Studies
Figure 10. Blood Disorders Case Studies
Figure 11. Growth Hormone Deficiency Case Studies
Figure 12. Infectious Diseases Case Studies
Figure 13. Other Diseases Case Studies
Figure 14. Peptides Biosimilars Report Years Considered
Figure 15. Global Peptides Biosimilars Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 16. Global Peptides Biosimilars Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 17. Global Peptides Biosimilars Market Share by Region: 2022 VS 2033
Figure 18. Global Peptides Biosimilars Market Share by Players in 2022
Figure 19. Global Top Peptides Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptides Biosimilars as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Peptides Biosimilars Revenue in 2022
Figure 21. North America Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. North America Peptides Biosimilars Market Share by Type (2018-2033)
Figure 23. North America Peptides Biosimilars Market Share by Application (2018-2033)
Figure 24. North America Peptides Biosimilars Market Share by Country (2018-2033)
Figure 25. United States Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Canada Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Europe Peptides Biosimilars Market Size YoY (2018-2033) & (US$ Million)
Figure 28. Europe Peptides Biosimilars Market Share by Type (2018-2033)
Figure 29. Europe Peptides Biosimilars Market Share by Application (2018-2033)
Figure 30. Europe Peptides Biosimilars Market Share by Country (2018-2033)
Figure 31. Germany Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. France Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. U.K. Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Italy Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Russia Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Nordic Countries Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. China Peptides Biosimilars Market Size YoY (2018-2033) & (US$ Million)
Figure 38. China Peptides Biosimilars Market Share by Type (2018-2033)
Figure 39. China Peptides Biosimilars Market Share by Application (2018-2033)
Figure 40. Asia Peptides Biosimilars Market Size YoY (2018-2033) & (US$ Million)
Figure 41. Asia Peptides Biosimilars Market Share by Type (2018-2033)
Figure 42. Asia Peptides Biosimilars Market Share by Application (2018-2033)
Figure 43. Asia Peptides Biosimilars Market Share by Region (2018-2033)
Figure 44. Japan Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. South Korea Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. China Taiwan Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Southeast Asia Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. India Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Australia Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Peptides Biosimilars Market Size YoY (2018-2033) & (US$ Million)
Figure 51. Middle East, Africa, and Latin America Peptides Biosimilars Market Share by Type (2018-2033)
Figure 52. Middle East, Africa, and Latin America Peptides Biosimilars Market Share by Application (2018-2033)
Figure 53. Middle East, Africa, and Latin America Peptides Biosimilars Market Share by Country (2018-2033)
Figure 54. Brazil Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Mexico Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Turkey Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Saudi Arabia Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. Israel Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. GCC Countries Peptides Biosimilars Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 60. Sandoz Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 61. Pfizer Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 62. Teva Pahrmaceutical Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 63. Celltrion Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 64. Biocon Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 65. Amgen Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 66. Samsung Biologics Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 67. Mylan Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 68. Dr. Reddy's Laboratories Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 69. Stada Arzneimittel AG Revenue Growth Rate in Peptides Biosimilars Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries